Rose McNulty

Recent decades have seen marked improvements in hematological cancer outcomes and an expanded armamentarium of therapies, but novel treatments require updated strategies that are not always easy to fine-tune, according to presenters at the 2023 American Society of Hematology Annual Meeting and Exposition.

Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia (CLL) Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, discussed the updated findings from the phase 3 ALPINE trial of zanubrutinib vs ibrutinib in relapsed/refractory CLL (R/R CLL) at 39 months of follow-up.

Pharmacy stakeholders met in Newport Beach, California, for an Institute for Value-Based Medicine® event to discuss the intersection of value-based medicine and pharmacy.

Mrinal M. Gounder, MD, a sarcoma oncologist at Memorial Sloan Kettering Cancer Center and lead investigator of the phase 3 DeFi trial of nirogacestat in desmoid tumors, discusses the drug's recent FDA approval and potential impacts on desmoid tumor treatment going forward.

Mikkael A. Sekeres, MD, chief of the Division of Hematology at Sylvester Comprehensive Cancer Center, University of Miami, and chair of the American Society of Hematology (ASH) Committee on Communications, discusses the themes of the upcoming ASH Annual Meeting & Exposition 2023.

Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia (CLL) Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute, previewed her presentation of extended follow-up data from the phase 3 ALPINE trial and other studies of interest to CLL specialists at the 2023 American Society of Hematology (ASH) Annual Meeting.

Patients seen at value-based care clinics received more preventive screenings and had lower risks of hospitalization and emergency room visits, according to Humana’s 10th annual value-based care report.

Researchers found that core oncology services were less likely to be available at hospitals serving racial and ethnic minority groups compared with other hospitals in the United States.

Guru Sonpavde, MD, medical director of genitourinary oncology at the AdventHealth Cancer Institute, discussed the promising findings of the CheckMate 901 trial exploring the potential of nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma.

A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.

Urothelial carcinoma has long been treated with chemotherapy as the frontline standard of care, but recent trial results in the space have potential to add to the treatment armamentarium and improve outcomes for the first time in decades.

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discussed the impacts of immunotherapy on outcomes for certain patients with non–small cell lung cancer.

A cohort study of 65 clinical trials in multiple myeloma found that toxic effects are often described with subjective terminology that may not reflect adverse event rates reported in the studies.

Researchers concluded there is a clinically important increase in infection risk among patients with T1D in both primary care and hospital settings, and that guidelines must be developed to reflect this risk and encourage earlier treatment.

While the overall rate of cancer death among children has declined substantially in recent decades, progress has stalled for Black and Hispanic children compared with White children since 2011.

A recent review aimed to characterize the relationship between tumor burden and clinical outcomes in patients treated with chimeric antigen receptor (CAR) T-cell therapy, highlighting the potential mechanisms of high tumor burden impacting CAR T-cell failure.

In a recent study, reducing dietary sodium demonstrated a blood pressure–reducing effect similar to that of a commonly used first-line antihypertensive medication.

Alyson Moadel-Robblee, PhD, deputy director of community engagement and cancer health equity at Montefiore Einstein Comprehensive Cancer Center, discussed the center's evolving patient distress screening process and the Bronx Oncology Living Daily support program for patients with cancer.

Michael Yim, MD, board-certified family physician, discussed the need for and logistics of collaboration between oncologists and primary care providers.

Remibrutinib, an investigational, highly selective Bruton tyrosine kinase inhibitor, showed favorable results in the treatment of chronic spontaneous urticaria (CSU) in as early as 2 weeks in the phase 3 REMIX-1 and REMIX-2 studies.

Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.

The findings suggest the presence of CHIP before HCT may have potential to serve as a biomarker for CVD risk after HCT in patients with multiple myeloma.

In an interview with The American Journal of Managed Care®, Grant Andres, BSc, DC, BSN, MSN-RN, senior director of clinical operations at Arizona Oncology, discussed the nuances of successfully implementing value-based care initiatives across a large organization.

Mark A. Socinski, MD, discussed how the understanding of lung cancer has evolved over time, as well as how its heterogeneity impacts treatment strategies.

The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant consideration of pharmacotherapy, and 1 in 48 had high levels of LDL-C that are indicated for medication.

The annual Patient-Centered Oncology Care® (PCOC) meeting returns to Nashville, Tennessee, on November 7-8, bringing oncology stakeholders together for 2 days of discussions and presentations on the rapidly changing oncology care landscape.

A study evaluating disparities among children with acute leukemia found that Black children are more likely to present with higher disease burden at diagnosis compared with non-Hispanic White children.

High glucose variability in children and young adults with type 1 diabetes (T1D) strongly predicted slowed nerve conduction velocity, a forerunner of diabetic peripheral neuropathy, in a recent study.

The approval, which is based on results from the phase 3 KEYNOTE-966 trial, marks the sixth indication for pembrolizumab in gastrointestinal cancer.

A report published by the Urban Institute estimates that if the 10 Medicaid nonexpansion states were to implement expansions in 2024, Medicaid enrollment would increase by 5 million people, and 2.3 million fewer individuals would be uninsured